Common Name |
Cefpodoxime
Description |
Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.
Structure |
MOLSDF3D-SDFPDBSMILESInChI View 3D Structure
Synonyms |
Value |
Source |
CefpodoximaChEBI
CefpodoximumChEBI
Cefpodoxime proxetilHMDB
CPDX-PRHMDB
RU 51807HMDB
Chemical Formlia |
C15H17N5O6S2
Average Molecliar Weight |
427.455
Monoisotopic Molecliar Weight |
427.062024681
IUPAC Name |
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Traditional Name |
cefpodoxime
CAS Registry Number |
82619-04-3
SMILES |
[H][C@]12SCC(COC)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)C1=CSC(N)=N1)C(O)=O
InChI Identifier |
InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
InChI Key |
WYUSVOMTXWRGEK-HBWVYFAYSA-N
Chemical Taxonomy |
Description |
This compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
Kingdom |
Organic compounds
Super Class |
Organoheterocyclic compounds
Class |
Lactams
Sub Class |
Beta lactams
Direct Parent |
Cephalosporins
Alternative Parents |
N-acyl-alpha amino acids and derivatives
2,4-disubstituted thiazoles
1,3-thiazines
2-amino-1,3-thiazoles
Tertiary carboxylic acid amides
Heteroaromatic compounds
Secondary carboxylic acid amides
Amino acids
Azetidines
Dialkylthioethers
Dialkyl ethers
Carboxylic acids
Azacyclic compounds
Thiohemiaminal derivatives
Monocarboxylic acids and derivatives
Organopnictogen compounds
Carbonyl compounds
Primary amines
Hydrocarbon derivatives
Organic oxides
Substituents |
Cephalosporin
N-acyl-alpha amino acid or derivatives
Alpha-amino acid or derivatives
2,4-disubstituted 1,3-thiazole
Meta-thiazine
1,3-thiazol-2-amine
Heteroaromatic compound
Azole
Thiazole
Tertiary carboxylic acid amide
Amino acid or derivatives
Amino acid
Azetidine
Carboxamide group
Secondary carboxylic acid amide
Thioether
Hemithioaminal
Carboxylic acid derivative
Dialkylthioether
Monocarboxylic acid or derivatives
Ether
Dialkyl ether
Azacycle
Carboxylic acid
Organic nitrogen compound
Organonitrogen compound
Organooxygen compound
Carbonyl group
Primary amine
Hydrocarbon derivative
Organic oxide
Amine
Organopnictogen compound
Organic oxygen compound
Aromatic heteropolycyclic compound
Molecliar Framework |
Aromatic heteropolycyclic compounds
External Descriptors |
cephalosporin (CHEBI:3504 )
carboxylic acid (CHEBI:3504 )
Ontology |
Status |
Expected but not Quantified
Origin |
Drug
Biofunction |
Anti-Bacterial Agents
Antibacterial Agents
Cephalosporins
Application |
Pharmaceutical
Cellliar locations |
Membrane
Physical Properties |
State |
Solid
Experimental Properties |
Property |
Value |
Reference |
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water Solubility1.85e-01 g/LNot Available
LogPNot AvailableNot Available
Predicted Properties |
Property |
Value |
Source |
Water Solubility0.18 mg/mLALOGPS
logP0.05ALOGPS
logP-1.2ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)3.22ChemAxon
pKa (Strongest Basic)4.16ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area156.44 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity100.71 m3·mol-1ChemAxon
Polarizability39.9 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rlie of FiveYesChemAxon
Ghose FilterYesChemAxon
Vebers RlieYesChemAxon
MDDR-like RlieYesChemAxon
Spectra |
Spectra |
Spectrum Type |
Description |
Splash Key |
|
Predicted LC-MS/MS |
Predicted LC-MS/MS Spectrum – 10V, PositiveNot Available
Predicted LC-MS/MS |
Predicted LC-MS/MS Spectrum – 20V, PositiveNot Available
Predicted LC-MS/MS |
Predicted LC-MS/MS Spectrum – 40V, PositiveNot Available
Predicted LC-MS/MS |
Predicted LC-MS/MS Spectrum – 10V, NegativeNot Available
Predicted LC-MS/MS |
Predicted LC-MS/MS Spectrum – 20V, NegativeNot Available
Predicted LC-MS/MS |
Predicted LC-MS/MS Spectrum – 40V, NegativeNot Available
Biological Properties |
Cellliar Locations |
Membrane
Biofluid Locations |
Blood
Urine
Tissue Location |
Not Available
Pathways |
Not Available
Normal Concentrations |
Biofluid |
Status |
Age |
Condition |
Reference |
Details |
BloodExpected but not Quantified Not AvailableNot AvailableTaking drug identified by DrugBank entry DB01416
21059682
details
UrineExpected but not Quantified Not AvailableNot AvailableTaking drug identified by DrugBank entry DB01416
21059682
details
|
Abnormal Concentrations |
|
Not Available
Associated Disorders and Diseases |
Disease References |
None
Associated OMIM IDs |
None
External Links |
DrugBank ID |
DB01416
DrugBank Metabolite ID |
Not Available
Phenol Explorer Compound ID |
Not Available
Phenol Explorer Metabolite ID |
Not Available
FoodDB ID |
Not Available
KNApSAcK ID |
Not Available
Chemspider ID |
4891496
KEGG Compound ID |
C08114
BioCyc ID |
Not Available
BiGG ID |
Not Available
Wikipedia Link |
Cefpodoxime
NuGOwiki Link |
HMDB15486
Metagene Link |
HMDB15486
METLIN ID |
Not Available
PubChem Compound |
6335986
PDB ID |
Not Available
ChEBI ID |
3504
Product: Maribavir
References |
Synthesis Reference |
Not Available |
Material Safety Data Sheet (MSDS) |
Not Available |
General References |
- Fukutsu N, Sakamaki Y, Kawasaki T, Saito K, Nakazawa H: Verification of cefmetazole and cefpodoxime proxetil contamination to other pharmaceuticals by liquid chromatography-tandem mass spectrometry. Chem Pharm Bull (Tokyo). 2006 Oct;54(10):1469-72. [PubMed:17015995 ]
- Fukutsu N, Sakamaki Y, Kawasaki T, Saito K, Nakazawa H: LC/MS/MS method for the determination of trace amounts of cefmetazole and cefpodoxime proxetil contaminants in pharmaceutical manufacturing environments. J Pharm Biomed Anal. 2006 Jun 16;41(4):1243-50. Epub 2006 May 15. [PubMed:16704914 ]
|
PMID: 25788259